Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
复制标题
ERCC1，BAG-1，BRCA1，RRM1和TUBB3的mRNA表达的组合分析，以预测接受辅助化疗的非小细胞肺癌患者的预后。
DOI：
10.1186/1756-9966-31-25
复制
发表时间：
2012-03-23
期刊：
影响因子：
--
通讯作者：
Li MH
中科院分区：
文献类型：
--
作者：
Leng XF;Chen MW;Xian L;Dai L;Ma GY;Li MH
本研究旨在探讨切除修复交叉互补基因1（ERCC 1）、BCL 2相关的嗜酸基因（BAG-1）、乳腺癌和卵巢癌易感基因1（BRCA 1）、核糖核苷酸还原酶亚单位M1（RRM 1）和III类β-微管蛋白（TUBB 3）在接受含铂类辅助化疗的非小细胞肺癌（NSCLC）患者中的预后价值。采用半定量RT-PCR方法检测85例肿瘤组织和34例癌旁组织中这些基因的mRNA表达。分析这五个基因的表达与化疗和无进展生存期（PFS）和总生存期（OS）的关系。74例患者入组化疗。ERCC 1和BAG-1阴性表达患者的PFS（P = 0.001和P = 0.001）和OS（P = 0.001和P = 0.001）显著长于阳性表达患者。ERCC 1和BAG-1表达阴性的患者从铂类方案获益更多（P = 0.001和P = 0.002）。BRCA 1阴性表达患者的OS可能比BRCA 1阳性表达患者长（P = 0.052），但PFS无显著性差异（P = 0.088）。ERCC 1和BAG-1的mRNA表达之间存在显著相关性（P = 0.042）。在多因素分析中，ERCC 1和BAG-1是PFS（P = 0.018和P = 0.017）和OS（P = 0.027和P = 0.022）的显著有利因素。ERCC 1和BAG-1是NSCLC患者术后生存的决定因素，其mRNA表达水平可用于预测铂类药物治疗后NSCLC患者的预后。
The aim of this study was to investigate prognostic value of excision repair cross-complementing 1 (ERCC1), BCL2-associated athanogene (BAG-1), the breast and ovarian cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III β-tubulin (TUBB3) in patients with non-small cell lung cancer (NSCLC) who received platinum- based adjuvant chemotherapy. Messenger RNA expressions of these genes were examined in 85 tumor tissues and 34 adjacent tissue samples using semi-quantitative RT-PCR. The expressions of these five genes were analyzed in relation to chemotherapy and progression-free survival (PFS) and overall survival (OS). Seventy-four patients were enrolled into chemotherapy. Patients with ERCC1 or BAG-1 negative expression had a significantly longer PFS (P = 0.001 and P = 0.001) and OS (P = 0.001 and P = 0.001) than those with positive expression. Patients with negative ERCC1 and BAG-1 expression benefited more from platinum regimen (P = 0.001 and P = 0.002). Patients with BRCA1 negative expression might have a longer OS (P = 0.052), but not PFS (P = 0.088) than those with BRCA1 positive expression. A significant relationship was observed between the mRNA expression of ERCC1 and BAG-1 (P = 0.042). In multivariate analysis, ERCC1 and BAG-1 were significantly favorable factors for PFS (P = 0.018 and P = 0.017) and OS (P = 0.027 and P = 0.022). ERCC1 and BAG-1 are determinants of survival after surgical treatment of NSCLC, and its mRNA expression in tumor tissues could be used to predict the prognosis of NSCLC treated by platinum.
登录
查看更多内容
影响因子：
4.5
作者：
Kim D;Jung W;Koo JS
通讯作者：
Koo JS
影响因子：
45.3
作者：
Bepler, Gerold;Kusmartseva, Irina;Simon, George
通讯作者：
Simon, George
BAG-1 基因沉默调节凋亡基因并使肺癌细胞系对顺铂诱导的细胞凋亡敏感
影响因子：
3.6
作者：
Liu, Hongyu;Liang, Yonggang;Zhou, Qinghua
通讯作者：
Zhou, Qinghua
晚期非小细胞肺癌ERCC1、RRM1、BRCA1 mRNA表达水平与临床转归
影响因子：
3.4
作者：
Su, Chunxia;Zhou, Songwen;Zhou, Caicun
通讯作者：
Zhou, Caicun
影响因子：
45.3
作者：
Cobo, Manuel;Isla, Dolores;Rosell, Rafael
通讯作者：
Rosell, Rafael